SPONSOR
National Cancer Institute (NCI)
Total Trials
51
Recruiting
51
Phases
Phase 1, Phase 2, Phase 1, Phase 2, Phase 3, Phase 2, Phase 3
Conditions studied: Prostate CancerCancer Of ProstateProstatic NeoplasmsMetastatic Prostate CancerProstateLymphomaNon-Hodgkin LymphomaDiffuse Large B-Cell LymphomaBurkitt LymphomaPediatric Cancer
NCT04706663
Recruiting
Precision-Based Genomics in Prostate Cancer
Prostate Cancer
NCT00923221
Recruiting
Collection of Blood From Patients With Prostate Cancer
Cancer Of Prostate
NCT04739813 Phase 1
Recruiting
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Lymphoma
NCT00001186
Recruiting
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
NCT05907759 Phase 2
Recruiting
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Lymphoma, Primary Effusion
NCT04929028 Phase 2
Recruiting
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
AIDS-Related Anal Carcinoma
NCT03907475 Phase 2
Recruiting
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Locally Advanced Malignant Solid Neoplasm
NCT04704661 Phase 1
Recruiting
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Advanced Breast Carcinoma
NCT06161545 Phase 2
Recruiting
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Stage II Squamous Cell Carcinoma of the Head and Neck
NCT02146170
Recruiting
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Non-Small Cell Lung Cancer
NCT01834001
Recruiting
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Prostatic Neoplasms
NCT05687123 Phase 1
Recruiting
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Metastatic Pancreatic Neuroendocrine Tumor
NCT05588154
Recruiting
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Myelodysplastic Syndromes
NCT05616650 Phase 2
Recruiting
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Prostatic Neoplasms
NCT04923178
Recruiting
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Urothelial Cancer
NCT05350761
Recruiting
Rare Tumors and Cancer Predisposition in Individuals and Families
Cancer
NCT06096870 Phase 2
Recruiting
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Prostate Cancer
NCT06514261 Phase 1
Recruiting
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Acute Myeloid Leukemia
NCT06865664 Phase 1
Recruiting
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Rhabdomyosarcoma
NCT05389423 Phase 1
Recruiting
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Diffuse Large Cell Lymphoma
NCT03816345 Phase 1
Recruiting
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Autoimmune Disease
NCT06439836 Phase 1
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Metastatic Urothelial Carcinoma
NCT05053971 Phase 1, Phase 2
Recruiting
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Advanced Malignant Solid Neoplasm
NCT04550494 Phase 2
Recruiting
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8
NCT06222203
Recruiting
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
Neurofibromatosis 1
NCT02579967 Phase 2
Recruiting
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Primary T-cell Immunodeficiency Disorders
NCT07003295 Phase 2
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Recurrent Mantle Cell Lymphoma
NCT04235764
Recruiting
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Bladder Cancer
NCT01660984
Recruiting
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Medullary Thyroid Cancer
NCT04665739 Phase 2
Recruiting
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Advanced Lung Neuroendocrine Tumor
NCT05849480 Phase 1, Phase 2
Recruiting
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Biliary Cancer
NCT06498635 Phase 3
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma
NCT01676805
Recruiting
Tissue Collection for Studies of Lymph Cancer
Hodgkin Disease
NCT06317662 Phase 2
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Acute Leukemia of Ambiguous Lineage
NCT05112601 Phase 2
Recruiting
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma
NCT07061951 Phase 2
Recruiting
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
NCT07061964 Phase 2
Recruiting
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial Carcinoma
NCT04166409 Phase 3
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma
NCT05286814 Phase 2
Recruiting
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Metastatic Colorectal Cancer (Mcrc)
NCT06149481 Phase 1, Phase 2
Recruiting
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
NCT06203600 Phase 2, Phase 3
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Advanced Esophageal Adenocarcinoma
NCT04145141
Recruiting
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Hepatocellular Carcinoma
NCT03739827
Recruiting
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Malignant Solid Tumors
NCT06303193 Phase 1, Phase 2
Recruiting
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
NCT05327023 Phase 1, Phase 2
Recruiting
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Hematologic Neoplasms
NCT06161506 Phase 2
Recruiting
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
Urinary Urge Incontinence
NCT05470491 Phase 1, Phase 2
Recruiting
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
HIV
NCT06980038 Phase 2
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
NCT05773274 Phase 2
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Metastatic Digestive System Neuroendocrine Tumor G1
NCT00092235
Recruiting
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Chronic Graft vs. Host Disease
NCT06223568 Phase 2
Recruiting
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Squamous Cell Carcinoma of the Head and Neck